Isatuximab

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM) . Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions[1][2].

Product Specifications

CAS Number

[1461640-62-9]

Product Name Alternative

Ch38SB19; hu38SB19; SAR-650984

UNSPSC

12352203

Target

Apoptosis

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/isatuximab.html

Purity

98.5

Solubility

H2O

Smiles

[Isatuximab]

Molecular Weight

(145.2 kDa)

References & Citations

[1]Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23; :]. Drugs. 2020;80 (9) :905-912.|[2]Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM) : a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394 (10214) :2072]. Lancet. 2019;394 (10214) :2096-2107.